PharmaCyte Biotech (NASDAQ:PMCB) Shares Up 2%

PharmaCyte Biotech, Inc. (NASDAQ:PMCBGet Free Report)’s stock price shot up 2% during trading on Thursday . The company traded as high as $2.06 and last traded at $2.02. 14,115 shares changed hands during trading, a decline of 31% from the average session volume of 20,547 shares. The stock had previously closed at $1.98.

PharmaCyte Biotech Stock Up 2.0 %

The company’s 50 day simple moving average is $2.22 and its two-hundred day simple moving average is $2.18. The company has a market capitalization of $17.07 million, a price-to-earnings ratio of -1.68 and a beta of -0.13.

PharmaCyte Biotech (NASDAQ:PMCBGet Free Report) last posted its quarterly earnings data on Monday, March 18th. The company reported ($0.65) earnings per share for the quarter.

Institutional Investors Weigh In On PharmaCyte Biotech

An institutional investor recently raised its position in PharmaCyte Biotech stock. K2 Principal Fund L.P. raised its position in shares of PharmaCyte Biotech, Inc. (NASDAQ:PMCBFree Report) by 67.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 258,481 shares of the company’s stock after purchasing an additional 104,249 shares during the quarter. K2 Principal Fund L.P. owned 2.94% of PharmaCyte Biotech worth $543,000 at the end of the most recent reporting period. 34.24% of the stock is currently owned by institutional investors and hedge funds.

PharmaCyte Biotech Company Profile

(Get Free Report)

PharmaCyte Biotech, Inc, a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.

Read More

Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with's FREE daily email newsletter.